IQVIA Holdings Inc. $IQV Shares Bought by Callan Family Office LLC

Callan Family Office LLC boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 342.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,227 shares of the medical research company’s stock after buying an additional 4,819 shares during the quarter. Callan Family Office LLC’s holdings in IQVIA were worth $981,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd grew its position in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after buying an additional 131 shares during the period. Golden State Wealth Management LLC grew its position in shares of IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 130 shares during the period. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA in the first quarter valued at about $33,000. Larson Financial Group LLC grew its position in shares of IQVIA by 109.9% in the first quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after purchasing an additional 144 shares during the period. Finally, Atticus Wealth Management LLC acquired a new stake in shares of IQVIA in the second quarter valued at about $52,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider directly owned 2,910 shares of the company’s stock, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

IQV has been the topic of several research analyst reports. Truist Financial lifted their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. Evercore ISI lifted their target price on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research report on Wednesday. Redburn Partners set a $214.00 target price on shares of IQVIA in a research report on Wednesday, September 3rd. UBS Group lifted their target price on shares of IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. Finally, William Blair reissued an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $236.45.

IQVIA Stock Performance

NYSE:IQV opened at $198.35 on Monday. The company’s 50-day moving average price is $189.02 and its 200-day moving average price is $168.11. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The company has a market cap of $33.72 billion, a P/E ratio of 28.70, a P/E/G ratio of 2.18 and a beta of 1.32. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $237.34.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the previous year, the firm earned $2.64 earnings per share. IQVIA’s quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.